West Pharmaceutical Services (NYSE:WST) Issues FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.000-6.200 for the period, compared to the consensus estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on WST shares. Wolfe Research started coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a report on Friday. UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their target price for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Bank of America lifted their price target on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus price target of $344.00.

West Pharmaceutical Services Stock Up 11.5 %

Shares of NYSE:WST traded up $22.99 during midday trading on Friday, reaching $222.10. The company had a trading volume of 2,529,295 shares, compared to its average volume of 676,799. West Pharmaceutical Services has a 1-year low of $197.01 and a 1-year high of $400.88. The stock has a market cap of $16.08 billion, a PE ratio of 32.93, a P/E/G ratio of 19.31 and a beta of 1.01. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average price is $330.01 and its 200 day moving average price is $314.33.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. Research analysts forecast that West Pharmaceutical Services will post 6.67 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th were given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date was Friday, February 7th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.46%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.